<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964027</url>
  </required_header>
  <id_info>
    <org_study_id>SIEG</org_study_id>
    <nct_id>NCT01964027</nct_id>
  </id_info>
  <brief_title>The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer</brief_title>
  <acronym>SIEG</acronym>
  <official_title>The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anhui Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the response rate and safety profile of irinotecan plus epirubicin&#xD;
      as the second-line chemotherapy for advanced gastric cancer and fully evaluate the&#xD;
      feasibility and effectiveness of the regime.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purposes: to determine the progression-free survival (PFS) and overall survival (OS)&#xD;
      of gastric cancer patients given irinotecan + epirubicin as second-line treatment, who are at&#xD;
      Stage IV with disease progressed or recurred after first-line chemotherapy failed, ,&#xD;
&#xD;
      The Secondary purposes: to determine disease control rate (Disease Control Rate, DCR), the&#xD;
      objective response rate (Object Response rate, ORR) and the Quality of life (Quality Of Life,&#xD;
      QOL)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS and OS</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation progression-free survival (PFS) and overall survival (OS)&#xD;
RECIST(Response Evaluation Criteria In Solid Tumors)1.1:&#xD;
Complete response (CR)&#xD;
Partial response (PR)&#xD;
Stable disease(SD) and progression disease(PD)&#xD;
CR + PR is efficient.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Stage IV Gastric Cancer With Metastasis</condition>
  <arm_group>
    <arm_group_label>Irinotecan plus epirubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>second line chemoregime for advanced gastric cancer</intervention_name>
    <description>Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer</description>
    <arm_group_label>Irinotecan plus epirubicin</arm_group_label>
    <other_name>irinotecan plus epirubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Aged between 18 to 70 years&#xD;
&#xD;
          -  The pathologically confirmed gastric adenocarcinoma and the failure of first-line&#xD;
             chemotherapy&#xD;
&#xD;
          -  Measurable lesions outside the stomach&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group ) score between 0 to 1&#xD;
&#xD;
          -  Expected survival time of at least 3 months&#xD;
&#xD;
          -  Subjects receiving treatment for other damage caused has been restored, which it&#xD;
             accepted the nitroso or mitomycin interval&gt; 6 weeks, the acceptance of other cytotoxic&#xD;
             drugs, radiotherapy or surgery&gt; = 4 weeks, and the wound has completely healed. No&#xD;
             bleeding, no nervous system transferred&#xD;
&#xD;
          -  Blood and organ function was normal&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Comorbid with other malignant tumors&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  with the disease of endangering patient's safety and affecting the completion of the&#xD;
             study&#xD;
&#xD;
          -  Patients suffering from high blood pressure by antihypertensive treatment cannot&#xD;
             control (systolic blood pressure&gt; 140mmhg, diastolic blood pressure&gt; 90mmhg,) there is&#xD;
             more than Class I and Class I arrhythmia coronary heart disease, with more than Class&#xD;
             I heart dysfunction&#xD;
&#xD;
          -  Major organ failure, such as decompensated heart and lung failure, liver failure,&#xD;
             renal failure and patients with intestinal obstruction ipate in other clinical trials&#xD;
             of patients in the past four weeks&#xD;
&#xD;
          -  Participated in clinical trials with other drugs or using other drugs during past 4&#xD;
             weeks&#xD;
&#xD;
          -  Lesions which can't be measured such as pleural effusion, ascites, peritoneal cancer&#xD;
             lesions, diffuse liver and bone metastases violation, brain metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yueyin Pan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Anhui Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yueyin Pan, MD</last_name>
    <phone>865512922987</phone>
    <email>yueyinpan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology,The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yueyin Pan, MD</last_name>
      <phone>865512922987</phone>
      <email>yueyinpan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hu Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Anhui Medical University</investigator_affiliation>
    <investigator_full_name>Pan Yueyin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>second line chemoregime</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

